Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Artemis II astronauts race to set a new distance record from Earth and behold the moon's far side - 2Hyundai Is Keeping the i30 Alive While America Keeps Losing Cars Like It
- 3This Tiny Bright Yellow Frog Is One of the Most Toxic Animals on Earth
- 4Which European countries have mandatory or voluntary military service
- 57 Fun Plans to Make Film Evenings Seriously Energizing (You'll Cherish #5!)
- Hand Skin Is Additionally Significant - What You Ought to Realize About Hand Cream
- Cognizant Couture d: A Survey of \Moral Decisions and Sharp Looks\ Maintainable Style
- 9 African migrants died in freezing temperatures near Morocco-Algeria border
- Defence chiefs of Thailand and Cambodia to discuss ceasefire
- Hilary Duff's husband responds to Ashley Tisdale's 'toxic' mom group claims: The drama, explained
- Instructions to Pick the Right Tires for Your Slam 1500.
- Nine in 10 German industrial firms expect Iran war to hit business
- Was it a stone tool or just a rock? An archaeologist explains how scientists can tell the difference
- Simple Consideration Plants for Home and Office: An Aide
